Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $145.00 at UBS Group

Merck & Co., Inc. (NYSE:MRK) had its price objective upped by UBS Group from $130.00 to $145.00 in a report released on Monday morning,Benzinga reports. UBS Group currently has a buy rating on the stock.

A number of other analysts have also issued reports on the company. Wall Street Zen raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Saturday, March 28th. Wells Fargo & Company raised their price target on Merck & Co., Inc. from $135.00 to $150.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. JPMorgan Chase & Co. raised their price target on Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a research note on Monday, April 6th. Weiss Ratings reissued a “hold (c)” rating on shares of Merck & Co., Inc. in a research note on Monday, December 29th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $142.00 price target on shares of Merck & Co., Inc. in a research note on Monday, March 30th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $128.47.

Merck & Co., Inc. Stock Down 1.0%

MRK opened at $120.19 on Monday. The company has a quick ratio of 1.30, a current ratio of 1.54 and a debt-to-equity ratio of 0.89. The firm has a market cap of $296.86 billion, a P/E ratio of 16.51, a PEG ratio of 2.44 and a beta of 0.26. Merck & Co., Inc. has a 52 week low of $73.31 and a 52 week high of $125.14. The business’s fifty day simple moving average is $119.19 and its 200 day simple moving average is $105.13.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The business had revenue of $16.40 billion for the quarter, compared to analyst estimates of $16.19 billion. During the same quarter last year, the company earned $1.72 earnings per share. The business’s revenue for the quarter was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. As a group, equities research analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th were issued a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date was Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 46.70%.

Insider Buying and Selling

In other news, CMO Chirfi Guindo sold 20,000 shares of the firm’s stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $121.88, for a total value of $2,437,600.00. Following the transaction, the chief marketing officer directly owned 80,615 shares in the company, valued at $9,825,356.20. This trade represents a 19.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Richard R. Deluca sold 37,685 shares of the firm’s stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $120.92, for a total value of $4,556,870.20. Following the completion of the transaction, the executive vice president owned 160,174 shares in the company, valued at approximately $19,368,240.08. This trade represents a 19.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 320,176 shares of company stock worth $38,281,735. Corporate insiders own 0.13% of the company’s stock.

Hedge Funds Weigh In On Merck & Co., Inc.

Large investors have recently modified their holdings of the company. Kingdom Financial Group LLC. purchased a new position in shares of Merck & Co., Inc. in the 4th quarter worth about $25,000. Prosperity Bancshares Inc purchased a new position in shares of Merck & Co., Inc. in the 4th quarter worth about $26,000. Abound Financial LLC purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at about $26,000. IFC & Insurance Marketing Inc. purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at about $31,000. Finally, High Note Wealth LLC raised its holdings in shares of Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after buying an additional 109 shares during the period. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: UBS raised its price target on MRK to $145 and kept a Buy rating, increasing upside expectations and providing an analyst-led bullish signal. Benzinga
• Positive Sentiment: The FDA accepted and granted Priority Review to the BLA for ifinatamab deruxtecan (co-developed with Daiichi Sankyo) for previously treated extensive-stage small cell lung cancer — this could meaningfully expand Merck’s oncology franchise if approved. Ifinatamab Deruxtecan Granted Priority Review
• Positive Sentiment: Merck received expanded EU approval for KEYTRUDA‑based regimens in platinum‑resistant ovarian cancer and announced strong Phase 3 results for enlicitide decanoate (LDL lowering) with a near‑term FDA priority review filing planned — both support revenue diversification beyond existing indications. Merck Extends KEYTRUDA Reach
• Neutral Sentiment: “Big Pharma is thinking small” commentary notes industry M&A and deal discipline trends; smaller, targeted deals can help biotech partners and reduce mega‑deal risk for large pharma — a mixed structural factor for Merck’s M&A outlook. Big Pharma Is Thinking Small on Deals
• Neutral Sentiment: Sector headlines — including Eli Lilly’s strong run and other biotech successes — are drawing investor attention; competition and valuation rotations in healthcare can shift relative flows away from Merck in the near term. How Eli Lilly Stock Rises To $2,000
• Neutral Sentiment: Other sector moves (e.g., a biotech’s successful pancreatic cancer Phase 3 and Organon M&A rumors) are driving healthcare volatility but aren’t directly tied to Merck fundamentals. This Biotech Stock Soars 39%
• Negative Sentiment: A market write-up highlighted MRK “sinking” while broader markets gained, signaling investor profit‑taking or short‑term rotation out of the stock. This captures today’s downward price move and sentiment pressure. Merck (MRK) Stock Sinks As Market Gains
• Negative Sentiment: Morgan Stanley issued a Hold on MRK (reported via press coverage), a more cautious stance that can limit near‑term upside by tempering investor enthusiasm despite the UBS upgrade. Merck Gets a Hold from Morgan Stanley

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.